HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report.

Bromodomain and extraterminal protein Histone deacetylase Histone deacetylase inhibitors NUT gene NUT midline carcinoma Salivary gland

Journal

Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 16 11 2019
accepted: 11 01 2020
pubmed: 29 1 2020
medline: 14 9 2021
entrez: 29 1 2020
Statut: ppublish

Résumé

NUT midline carcinoma (NMC) is a recently described entity with a predilection for young individuals, characterised by a rearrangement of NUT, most commonly with BRD4. It usually involves midline structures, with a minority of cases presenting outside the midline axis. Given its dismal prognosis, new molecularly targeted therapies (eg, HDAC inhibitors) are gaining ground, but the HDAC expression pattern remains unknown. We describe the exceptional evolution of a NMC arising in the parotid gland. A 34-year-old male presented with a rapidly growing 35 mm left-parotid mass. Parotidectomy and lymphadenectomy were performed. The tumour invaded the surrounding soft tissue and lay adjacent to the surgical margin. No lymph node metastases were identified. Histology revealed blue nests of undifferentiated cells merging with foci of necrosis and occasional abrupt foci of keratinising squamous epithelium. FISH analysis confirmed a rearrangement of NUT, but not of BRD4. A diagnosis of NMC was rendered. Currently, after adjuvant chemoradiotherapy and 47 months after diagnosis, the patient is alive and well. The tumour was found to have increased immunoexpression of HDAC2, 4 and 6 and phospho-HDAC4/5/7. This case emphasises the importance of considering NMC in the differential diagnosis of poorly differentiated carcinomas of the head and neck region in young adults, even away from midline structures. As molecular targets hold the promise of successful therapy for the vast majority of NMC patients, the knowledge of their HDAC expression patterns will probably be relevant.

Identifiants

pubmed: 31989434
doi: 10.1007/s12105-020-01130-6
pii: 10.1007/s12105-020-01130-6
pmc: PMC7669913
doi:

Substances chimiques

NUTM1 protein, human 0
Neoplasm Proteins 0
Nuclear Proteins 0
Histone Deacetylases EC 3.5.1.98

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1117-1122

Références

Oncogene. 2008 Apr 3;27(15):2237-42
pubmed: 17934517
Head Neck Pathol. 2016 Sep;10(3):362-6
pubmed: 26586234
Oncol Lett. 2017 Jan;13(1):403-409
pubmed: 28123574
Aging (Albany NY). 2016 Jun;8(6):1236-49
pubmed: 27295551
BMC Cancer. 2006 Mar 16;6:69
pubmed: 16542442
Onco Targets Ther. 2019 Apr 30;12:3235-3244
pubmed: 31118674
Am J Surg Pathol. 2009 Aug;33(8):1253-8
pubmed: 19561446
Urol Oncol. 2013 Nov;31(8):1770-9
pubmed: 22944197
Am J Surg Pathol. 2009 Jul;33(7):984-91
pubmed: 19363441
Oncol Lett. 2018 Nov;16(5):6552-6560
pubmed: 30405794
Cancer Res. 2011 Apr 1;71(7):2686-96
pubmed: 21447744
Am J Pathol. 2001 Dec;159(6):1987-92
pubmed: 11733348
Cancer Lett. 2009 Aug 8;280(2):168-76
pubmed: 19103471
Diagn Cytopathol. 2016 Sep;44(9):753-6
pubmed: 27338676
Cancers (Basel). 2019 Mar 05;11(3):
pubmed: 30841549
Cancer Discov. 2016 May;6(5):492-500
pubmed: 26976114
Pediatr Blood Cancer. 2015 Apr;62(4):715-7
pubmed: 25557064
Cell Death Dis. 2018 Jul 26;9(8):817
pubmed: 30050135
Int J Oncol. 2006 Jul;29(1):117-24
pubmed: 16773191
Am J Surg Pathol. 2018 Jul;42(7):877-884
pubmed: 29649019
J Chemother. 2016 Jun;28(3):242-6
pubmed: 26027633
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
J Clin Pathol. 2010 Jun;63(6):492-6
pubmed: 18552174
Pediatr Blood Cancer. 2007 Dec;49(7):1015-7
pubmed: 16435379
Head Neck Pathol. 2017 Dec;11(4):460-468
pubmed: 28349372
Korean J Pathol. 2014 Aug;48(4):335-8
pubmed: 25214871
Cancer Res. 2003 Jan 15;63(2):304-7
pubmed: 12543779
Pediatr Cardiol. 2016 Jan;37(1):208-11
pubmed: 26667959
Genes Dev. 2015 Jul 15;29(14):1507-23
pubmed: 26220994
Hepatol Res. 2017 Feb;47(2):149-159
pubmed: 27457249
Pediatr Dev Pathol. 2010 Nov-Dec;13(6):481-5
pubmed: 20017639
Clin Cancer Res. 2012 Oct 15;18(20):5773-9
pubmed: 22896655
Eur Arch Otorhinolaryngol. 2018 Mar;275(3):815-821
pubmed: 29356890
J Clin Oncol. 2004 Oct 15;22(20):4135-9
pubmed: 15483023
Head Neck Pathol. 2010 Jun;4(2):163-8
pubmed: 20352379

Auteurs

Gonçalo Esteves (G)

Anatomic Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023, Lisboa, Portugal. gesteves@ipolisboa.min-saude.pt.
NOVA Medical School, Lisbon, Portugal. gesteves@ipolisboa.min-saude.pt.

Joana Ferreira (J)

Anatomic Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023, Lisboa, Portugal.
NOVA Medical School, Lisbon, Portugal.

Rita Afonso (R)

NOVA Medical School, Lisbon, Portugal.

Carmo Martins (C)

Molecular Pathology Research Unit (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisbon, Portugal.

Carlos Zagalo (C)

Department of Surgery of the Head and Neck, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisbon, Portugal.
Egas Moniz Interdisciplinary Investigation Centre (CiiEM), Lisbon, Portugal.

Ana Félix (A)

Anatomic Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023, Lisboa, Portugal.
NOVA Medical School, Lisbon, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH